Mobile

A phase 1/2, open-label study of bosutinib administered in combination with capecitabine in subjects with solid tumor and ErbB2 negative locally advanced or metastatic breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011878-15

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

For part 1, the primary objective is to assess the safety and tolerability, and to determine the MTD(s) of bosutinib plus capecitabine in patients with locally advanced or metastatic breast cancer or pancreatic cancer or colorectal cancer or cholangiocarcinoma or glioblastoma. For part 2, the primary objective is to determine the overall response rate (ORR) in women with ER+ and/or PgR+, erbB2- and ER-, PgR- erbB2- locally advanced or metastatic breast cancer.

Critère d'inclusion

  • Solid tumor and ErbB2 negative locally advanced or metastatic breast cancer

Liens